Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.
about
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.Afatinib in advanced NSCLC: a profile of its use.Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.Osimertinib in first line setting: preventive or delayed T790M occurrence?A Multicenter Study to Assess Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting
P2860
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Acquisition of the T790M resis ...... ncer harboring EGFR mutations.
@en
Acquisition of the T790M resis ...... ncer harboring EGFR mutations.
@nl
type
label
Acquisition of the T790M resis ...... ncer harboring EGFR mutations.
@en
Acquisition of the T790M resis ...... ncer harboring EGFR mutations.
@nl
prefLabel
Acquisition of the T790M resis ...... ncer harboring EGFR mutations.
@en
Acquisition of the T790M resis ...... ncer harboring EGFR mutations.
@nl
P2093
P2860
P356
P1433
P1476
Acquisition of the T790M resis ...... ncer harboring EGFR mutations.
@en
P2093
Akiko Fujii
Eiji Iwama
Hiroshi Ouchi
Hiroshi Wataya
Isamu Okamoto
Kaname Nosaki
Kentaro Tanaka
Kohei Otsubo
Koichi Azuma
Masafumi Takeshita
P2860
P304
68123-68130
P356
10.18632/ONCOTARGET.19243
P407
P577
2017-07-12T00:00:00Z